MADISON, WI USA (November 28, 2017)
Promega Corporation’s new NanoBRET™ Target Engagement (TE) Intracellular Kinase Assay is the first assay to quantify inhibitor drug binding to kinase proteins inside live human cells, as demonstrated in the recent Cell Chemical Biology article, “Quantitative, Wide-spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.” In collaboration with Structural Genomics Consortium (SGC), this article shows the greater predictive potential of NanoBRET Target Engagement compared to common traditional approaches that use purified kinase domains in non-cell-based assays.
“The NanoBRET TE assay is a major advance in our ability to demonstrate the potency and selectivity of kinase inhibitors in living cells,” says Tim Willson, Chief Scientist SGC-UNC. “Application of this technology to development of chemical probes will accelerate our study of the hundreds of dark kinases that may be new targets for drug discovery.”
NanoBRET TE uses bioluminescence resonance energy transfer (BRET) and allows measurement of drug binding to protein targets in real time inside live cells using a simplified experimental protocol. Accurate measurement of drug-target engagement in live cells is critical to understanding the biology of drug interactions against target proteins, with the ultimate aim of developing better therapies for human diseases.
The approach has proven beneficial for researchers at SGC-Frankfurt who are currently testing broad-spectrum profiling of specific kinase inhibitors in live cells for a more realistic estimate of inhibitor selectivity under more physiological conditions.
“We have already gained valuable insights regarding the kinetics of specific kinase inhibitors, and we also see great potential for this assay for other target families,” says Susanne Müller-Knapp, Senior Project Manager Chemical Probes, SGC Frankfurt.
The NanoBRET TE platform combines the sensitivity of NanoLuc® technology with quantitative capabilities of energy transfer. Unlike other methods, NanoBRET TE Kinase Assay allows for quantitative measurements of drug affinity and kinase selectivity inside live cells at target levels similar to that of endogenous kinases. To support kinase biology, Promega has just launched more than 100 individual full-length kinase target engagement assays.
To learn more about the new NanoBRET™ Target Engagement Intracellular Kinase Assay visit: www.promega.com/PRKinaseTE
A recent article in Cell Chemical Biology demonstrates that Promega Corporation’s new NanoBRET™ Target Engagement (TE) Intracellular Kinase Assay is the first assay to quantify inhibitor drug engagement with kinase proteins inside live human cells. Broad spectrum, quantitative live-cell profiling using full-length kinases reveals improved intracellular selectivity for clinically relevant kinase inhibitors compared to biochemical profiling. These live-cell kinase NanoBRET TE assays further enable a mechanistic assessment of the effect of cellular ATP on inhibitor potency.
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.
For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or via our contact page.